Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.

Gobbi S, Hu Q, Negri M, Zimmer C, Belluti F, Rampa A, Hartmann RW, Bisi A.

J Med Chem. 2013 Feb 28;56(4):1723-9. doi: 10.1021/jm301844q. Epub 2013 Feb 12.

PMID:
23363058
2.

Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.

Ulmschneider S, Müller-Vieira U, Mitrenga M, Hartmann RW, Oberwinkler-Marchais S, Klein CD, Bureik M, Bernhardt R, Antes I, Lengauer T.

J Med Chem. 2005 Mar 24;48(6):1796-805.

PMID:
15771425
3.

Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation.

Gobbi S, Zimmer C, Belluti F, Rampa A, Hartmann RW, Recanatini M, Bisi A.

J Med Chem. 2010 Jul 22;53(14):5347-51. doi: 10.1021/jm100319h.

PMID:
20568782
4.

Exploiting the Chromone Scaffold for the Development of Inhibitors of Corticosteroid Biosynthesis.

Gobbi S, Hu Q, Zimmer C, Engel M, Belluti F, Rampa A, Hartmann RW, Bisi A.

J Med Chem. 2016 Mar 24;59(6):2468-77. doi: 10.1021/acs.jmedchem.5b01609. Epub 2016 Mar 11.

PMID:
26938274
5.

N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).

Zimmer C, Hafner M, Zender M, Ammann D, Hartmann RW, Vock CA.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):186-90. doi: 10.1016/j.bmcl.2010.11.040. Epub 2010 Nov 12.

PMID:
21129965
6.

Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.

Hu Q, Yin L, Hartmann RW.

J Med Chem. 2012 Aug 23;55(16):7080-9. doi: 10.1021/jm3004637. Epub 2012 Aug 3.

PMID:
22861193
7.

Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.

Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, Barassin C, Marchais-Oberwinkler S, Hartmann RW.

J Med Chem. 2005 Oct 20;48(21):6632-42.

PMID:
16220979
9.

Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.

Yin L, Hu Q, Emmerich J, Lo MM, Metzger E, Ali A, Hartmann RW.

J Med Chem. 2014 Jun 26;57(12):5179-89. doi: 10.1021/jm500140c. Epub 2014 Jun 5.

PMID:
24899257
10.

Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.

Ulmschneider S, Müller-Vieira U, Klein CD, Antes I, Lengauer T, Hartmann RW.

J Med Chem. 2005 Mar 10;48(5):1563-75. Erratum in: J Med Chem. 2005 Jun 30;48(13):4489-90.

PMID:
15743198
11.

Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase.

Stefanachi A, Favia AD, Nicolotti O, Leonetti F, Pisani L, Catto M, Zimmer C, Hartmann RW, Carotti A.

J Med Chem. 2011 Mar 24;54(6):1613-25. doi: 10.1021/jm101120u. Epub 2011 Feb 22.

PMID:
21341743
12.

Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.

Hu Q, Yin L, Ali A, Cooke AJ, Bennett J, Ratcliffe P, Lo MM, Metzger E, Hoyt S, Hartmann RW.

J Med Chem. 2015 Mar 12;58(5):2530-7. doi: 10.1021/acs.jmedchem.5b00079. Epub 2015 Mar 3.

PMID:
25711516
13.

Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.

Papillon JP, Adams CM, Hu QY, Lou C, Singh AK, Zhang C, Carvalho J, Rajan S, Amaral A, Beil ME, Fu F, Gangl E, Hu CW, Jeng AY, LaSala D, Liang G, Logman M, Maniara WM, Rigel DF, Smith SA, Ksander GM.

J Med Chem. 2015 Jun 11;58(11):4749-70. doi: 10.1021/acs.jmedchem.5b00407. Epub 2015 May 21.

PMID:
25953419
14.

Imidazolylmethylbenzophenones as highly potent aromatase inhibitors.

Gobbi S, Cavalli A, Negri M, Schewe KE, Belluti F, Piazzi L, Hartmann RW, Recanatini M, Bisi A.

J Med Chem. 2007 Jul 26;50(15):3420-2. Epub 2007 Jun 22.

PMID:
17585752
15.

Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.

Yin L, Lucas S, Maurer F, Kazmaier U, Hu Q, Hartmann RW.

J Med Chem. 2012 Jul 26;55(14):6629-33. doi: 10.1021/jm3003872. Epub 2012 Jul 12.

PMID:
22788843
16.

A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase.

Recanatini M, Bisi A, Cavalli A, Belluti F, Gobbi S, Rampa A, Valenti P, Palzer M, Palusczak A, Hartmann RW.

J Med Chem. 2001 Mar 1;44(5):672-80.

PMID:
11262078
17.

Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.

Grombein CM, Hu Q, Rau S, Zimmer C, Hartmann RW.

Eur J Med Chem. 2015 Jan 27;90:788-96. doi: 10.1016/j.ejmech.2014.12.022. Epub 2014 Dec 13.

PMID:
25528333
18.

The potential of targeting CYP11B.

Bernhardt R.

Expert Opin Ther Targets. 2016 Aug;20(8):923-34. doi: 10.1517/14728222.2016.1151873. Epub 2016 Mar 2. Review.

PMID:
26854589
19.

Targeting Steroidogenic Cytochromes P450 (CYPs) with 6-Substituted 1-Imidazolylmethylxanthones.

Gobbi S, Hu Q, Zimmer C, Belluti F, Rampa A, Hartmann RW, Bisi A.

ChemMedChem. 2016 Aug 19;11(16):1770-7. doi: 10.1002/cmdc.201600078. Epub 2016 Apr 13.

PMID:
27071740
20.

Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.

Stefanachi A, Hanke N, Pisani L, Leonetti F, Nicolotti O, Catto M, Cellamare S, Hartmann RW, Carotti A.

Eur J Med Chem. 2015 Jan 7;89:106-14. doi: 10.1016/j.ejmech.2014.10.021. Epub 2014 Oct 13.

PMID:
25462231

Supplemental Content

Support Center